Evaluating how uncertainty about new cancer drugs affects patient decisions
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
NA · London School of Economics and Political Science · NCT06997185
This study is testing how different ways of talking about the uncertainties of new cancer drugs affect how people understand and decide whether to use them.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London School of Economics and Political Science (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT06997185 on ClinicalTrials.gov |
What this trial studies
This study involves a nationally representative survey of US adults to assess how different statements about uncertainties related to new cancer drugs influence participants' understanding and decision-making. Participants will first evaluate a hypothetical drug for non-small cell lung cancer and express their likelihood of using it. They will then be randomized to receive one of five statements that communicate various sources of uncertainty regarding the drug's clinical evidence, including trial design and treatment effect size. The goal is to improve communication about the risks and benefits of new cancer therapies.
Who should consider this trial
Good fit: Ideal candidates for this study are English-speaking adults aged 18 and older residing in the United States.
Not a fit: Patients who are not fluent in English or do not meet the age and residency criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance patient understanding and decision-making regarding new cancer treatments.
How similar studies have performed: While the approach of communicating uncertainties is gaining attention, this specific methodology has not been widely tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults 18 years of age and older * Adults fluent in English * Adults residing in the United States Exclusion Criteria: * Participants who do not meet each of the 3 inclusion criteria
Where this trial is running
Boston, Massachusetts
- Harvard Medical School and Harvard Pilgrim Health Care Institute — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Study coordinator: Avi Cherla
- Email: a.j.cherla@lse.ac.uk
- Phone: 16172011718
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Uncertainty, Prescription drug information